Grifols, S.A. Share Price OTC Markets

Equities

GIKLY

US3984382008

Pharmaceuticals

Delayed OTC Markets 16:38:54 14/05/2024 BST 5-day change 1st Jan Change
5.46 USD +3.80% Intraday chart for Grifols, S.A. +6.64% -37.24%

Financials

Sales 2024 * 7.08B 7.69B 608B Sales 2025 * 7.58B 8.23B 651B Capitalization 6.1B 6.62B 523B
Net income 2024 * 416M 452M 35.71B Net income 2025 * 697M 757M 59.82B EV / Sales 2024 * 2.17 x
Net Debt 2024 * 9.25B 10.04B 794B Net Debt 2025 * 8.72B 9.47B 749B EV / Sales 2025 * 1.95 x
P/E ratio 2024 *
13.3 x
P/E ratio 2025 *
9.49 x
Employees 23,744
Yield 2024 *
-
Yield 2025 *
2.58%
Free-Float 89.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.80%
1 week+6.64%
Current month+24.09%
1 month+19.74%
3 months-2.50%
6 months-21.25%
Current year-37.24%
More quotes
1 week
4.98
Extreme 4.98
5.46
1 month
4.40
Extreme 4.4
5.46
Current year
3.56
Extreme 3.564
8.00
1 year
3.56
Extreme 3.564
8.70
3 years
3.56
Extreme 3.564
14.04
5 years
0.00
Extreme 0
17.95
10 years
0.00
Extreme 0
17.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 02-05
Director of Finance/CFO 67 31/12/06
Chairman 65 04/04/06
Members of the board TitleAgeSince
Chairman 65 04/04/06
Director/Board Member 68 12/04/00
Director/Board Member 61 26/07/01
More insiders
Date Price Change Volume
14/05/24 5.46 +3.80% 1,000
13/05/24 5.26 +5.62% 75,160
10/05/24 4.98 +2.26% 92,205
09/05/24 4.87 -4.88% 42,234
08/05/24 5.12 +2.40% 378

Delayed Quote OTC Markets, May 14, 2024 at 04:38 pm

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
10.18 EUR
Average target price
16.81 EUR
Spread / Average Target
+65.10%
Consensus